CBS 2019
CBSMD教育中心
中 文

科学研究

Abstract

Recommended Article

Potential protective mechanisms of green tea polyphenol EGCG against COVID-19 Glucose-lowering Drugs or Strategies, Atherosclerotic Cardiovascular Events, and Heart Failure in People With or at Risk of Type 2 Diabetes: An Updated Systematic Review and Meta-Analysis of Randomised Cardiovascular Outcome Trials Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease Radial Versus Femoral Access for Rotational Atherectomy: A UK Observational Study of 8622 Patients The outcomes of intravascular ultrasound-guided drug-eluting stent implantation among patients with complex coronary lesions: a comprehensive meta-analysis of 15 clinical trials and 8,084 patients Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes Limitations of Repeat Revascularization as an Outcome Measure

Editorial2017 Oct 1;2(10):1061-1062.

JOURNAL:JAMA Cardiol. Article Link

What Is the Optimal Revascularization Strategy for Left Main Coronary Stenosis?

Ruel M, Verma S, Bhatt DL. Keywords: PCI; CABG; repeat revascularization

ABSTRACT

Over the last months, 2 major trials and several meta-analyses have been published on the treatment of stable, unprotected left main coronary artery stenosis. Currently, North American and European guidelines for the treatment of left main stenosis indicate a class I recommendation for the performance of coronary artery bypass grafting (CABG). They also indicate a class IIa to III (North American) or a class I to III (European) recommendation for percutaneous coronary intervention (PCI), depending on the complexity of the coronary anatomy as determined by the Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) score.